alexa Natriuretic Peptide-guided therapy for heart failure.
Cardiology

Cardiology

Journal of Clinical & Experimental Cardiology

Author(s): Mentz RJ, Felker GM

Abstract Share this page

Abstract Chronic heart failure (HF) remains a major medical problem in the developed world, with rapidly rising prevalence, substantial morbidity, and high costs. The concept of titrating chronic HF therapies using physiologic markers, so called "biomarker guided therapy (BGT)", has become an area of substantial interest in HF given the underutilization of evidence-based medications and suboptimal outcomes with current management strategies. Several recent trials of BGT have had mixed results, with some demonstrating improved outcomes and others showing no benefit. The heterogeneity of patient populations compounded by the lack of standardized BGT algorithms and trial endpoints has complicated interpretation of these results. This article reviews the rationale, accumulated data, and unanswered questions for BGT in chronic HF.
This article was published in Circ J and referenced in Journal of Clinical & Experimental Cardiology

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords